A study to investigate VMX-C001 in healthy volunteers.

2024-514339-87-00 Protocol VMX-C001-02 Human pharmacology (Phase I) - Other Ended

Start 14 Aug 2024 · End 13 Apr 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol VMX-C001-02

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 12
Countries 1
Sites 1

To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.

Key facts

Sponsor
VarmX B.V.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Phenomena and Processes [G] - Circulatory and Respiratory Physiological Phenomena [G09]
Trial duration
14 Aug 2024 → 13 Apr 2026
Decision date (initial)
2024-05-29
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514339-87-00
EudraCT number
2022-003675-41

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

To restore coagulation in patients taking DOACs who are experiencing bleeding or who require reversal of anticoagulation prior to urgent surgery.

VersionLevelCodeTermSystem organ class
20.0 PT 10009773 Coagulation factor X level 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

VarmX B.V.

Sponsor organisation
VarmX B.V.
Address
Emmy Noetherweg 2
City
Leiden
Postcode
2333 BK
Country
Netherlands

Scientific contact point

Organisation
VarmX B.V.
Contact name
CMO

Public contact point

Organisation
VarmX B.V.
Contact name
CMO

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ended 12 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ended
Pharma Bio-Research Group
Clinical Pharmacology, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2024-08-14 2026-04-13 2024-08-14 2024-10-30

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-17 Netherlands Acceptable
2024-05-29
2024-05-29
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-28 Netherlands Acceptable
2024-08-07
2024-08-07
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-10-02 Netherlands Acceptable
2024-08-07
2024-10-02
4 NON SUBSTANTIAL MODIFICATION NSM-3 2025-10-21 Netherlands Acceptable
2024-08-07
2025-10-21
5 NON SUBSTANTIAL MODIFICATION NSM-4 2026-02-03 Netherlands Acceptable
2024-08-07
2026-02-03